Aric Adaoag
Family · Las Vegas, NVNPI 1003262296
Payments from drug & device makers
Across 144 payments — averaging $26.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biohaven Pharmaceuticals, Inc.$987
- Amgen$681
- AstraZeneca$637
- Novo Nordisk$357
- Lilly USA, LLC$342
- Boehringer Ingelheim$302
- plus $554 from 12 others
What the payments were for
- Consulting fees$80021%
- Food & beverage$3,06079%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biohaven Pharmaceuticals, Inc. | 8 | $987 |
| Amgen(2 entities) | 32 | $681 |
| AstraZeneca | 27 | $637 |
| Novo Nordisk | 14 | $357 |
| Lilly USA, LLC | 18 | $342 |
| Boehringer Ingelheim | 12 | $302 |
| Kowa Pharmaceuticals America, Inc. | 4 | $81 |
| Arbor Pharmaceuticals, Inc. | 6 | $80 |
| Daiichi Sankyo Inc. | 4 | $78 |
| Pfizer | 4 | $61 |
| Exact Sciences | 3 | $54 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $46 |
| Amarin Pharma, Inc. | 2 | $39 |
| Azurity Pharmaceuticals, Inc. | 2 | $36 |
| AbbVie | 2 | $25 |
| Lucid Diagnostics Inc. | 1 | $25 |
| Merck | 1 | $17 |
| Dexcom, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$926
- BREZTRI$125
- JARDIANCE$119
- RYBELSUS$117
How this compares
$3,860 in reported general payments places this provider in the 90th percentile of 1,501 family providers in Nevada.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 31 | $33,382 |
| MounjaroTirzepatide | 13 | $25,407 |
| Repatha SureclickEvolocumab | 14 | $10,673 |
| Atorvastatin Calcium | 147 | $1,752 |
| Ezetimibe | 25 | $544 |
| Metformin Hcl | 45 | $455 |
| Fenofibrate | 12 | $412 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 15 | $404 |
| Alendronate Sodium | 26 | $372 |
| Amlodipine Besylate | 47 | $356 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 12 | $279 |
| Lisinopril | 53 | $249 |
| Levocetirizine Dihydrochloride | 11 | $193 |
| Losartan Potassium | 53 | $181 |
| Omeprazole | 13 | $167 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $302 | $33,38231 claims |
| Lilly USA, LLCMounjaro | $342 | $25,40713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,501 family providers in Nevada.
Other family in Las Vegas
- John PhoenixLas Vegas$281K
- Hollie TylerLas Vegas$118K
- Jon FaillaLas Vegas$74K
- Alex LapasaranLas Vegas$50K
- Kelly PapeshLas Vegas$44K
- Erin WilkinsonLas Vegas$43K
- Anna Melisa Lopez-SanglayLas Vegas$42K
- Bernard BlanksLas Vegas$26K
- Hillary DursteinLas Vegas$21K
- Victoria HughesLas Vegas$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.